Current Issues of Pharmacy and Medical Sciences

Blood serum amino acids profile in patients with Multiple Sclerosis

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 1, Pages 50-53


Department of Laboratory Diagnostics, Medical University of Lublin, Poland

DOI: 10.12923/j.2084-980X/26.1/a.10



Multiple sclerosis is the most common demyelinating disease of the central nervous system, affecting mostly young people. There were many risk factors for MS identified, however a direct cause of the disease is still unknown. Pathological changes in the SM lead to the myelin sheath damage around axons, what prevents proper transmission of nerve impulses in the central nervous system. The aim of this study was analyzing and comparing the amino acids profile in the blood serum of MS patients to control group of healthy individuals and evaluating the relationship between them. Significant (p<0.05) differences in the level of glutamate, aspartate and taurine in the blood serum of MS patients were revealed. A positive glutamate and aspartate level correlation in the serum has been demonstrated. Gender is significant only in the case of glutamate level in blood serum. The studies highlight the important role of neurotransmitters in MS and are the initial step in proteomic research.


Multiple sclerosis (MS), amino acid, aspartic acid, glutamic acid, taurine


  1. Barkhatova V.P. et al.: Changes in neurotransmitters in multiple sclerosis. Neurosci Behav Physiol, 28, 4, 1998.
  2. Bates Ian R., et al.: An Arg/Lys → Gln mutant of recombinant murine myelin basic protein as a mimic of the deiminated form implicated in multiple sclerosis. Protein Expr Purif, 25, 330–341, 2002.
  3. Fernando D.: Sclerosis Multiple. Neurology, 2010.
  4. Gauderman W-J, Cozen W, Mack T-M.: Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins Talat Islam. Neurology, 69, 381-388, 2007
  5. Hafler D.A. et al.: Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. N Eng J Med, 357 (9), 851-862, 2007.
  6. Haines J.D, Inglese M, Casaccia P.: Axonal Damage in Multiple Sclerosis. Mt Sinai J Med, 78(2), 231–243, 2011.
  7. Harauz G., Abdiwahab A. Musse.: A Tale of Two Citrullines—Structural and Functional Aspects of Myelin Basic Protein Deimination in Health and Disease. Neurochem Res, 32,137–158, 2007.
  8. Lassmann H.: Experimental models of multiple sclerosis. Rev Neurol, 163 (6–7), 651–655, 2007.
  9. Levin LI, et al.: Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA, 2496-2500, 2005.
  10. Liberski P.P. et al. (2005). Choroby demielinizacyjne . Neuropatologia Mossakowskiego. Lublin: Wydawnictwo Czelej; p.161-174.
  11. Lucchinetti C, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol, 47 (6), 707-717, 2000.
  12. Mouzaki A, et al.: Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab. Int J Gen Med, 3, 313-320, 2010.
  13. Munger K-L. et al.: Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis. JAMA, 296 (23), 2832-2838, 2006.
  14. Pascual AM, et al.: Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 69 (1), 63–67, 2007.
  15. Pierrot-Deseilligny C.: Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol, 1468-1479, 2009.
  16. Ponsonby A.-L. et al.: Exposure to Infant Siblings During Early Life and Risk of Multiple Sclerosis. JAMA, 293(4), 463-469, 2005.
  17. Renoux C. et al.: Natural History of Multiple Sclerosis with Childhood Onset. N Engl J Med, 356, 2603-13, 2007.
  18. Rentzos M. et al.: Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg, 108 (6), 527–531, 2006.
  19. Richard A. et al.: Gray-Matter Injury in Multiple Sclerosis. N Eng J Med, 361(15), 1505 – 1506, 2009.
  20. Srinivasan R. et al.: Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain, 128, 1016–1025, 2005.
  21. Sternberg Z. et al.: Acamprosate modulates experimental autoimmune encephalomyelitis. Inflammopharmacology, 20(1), 39-48, 2012.
  22. Su Kimmy G. et al.: Axonal degeneration in multiple sclerosis: The mitochondrial hypotesis. Curr Neurol Neurosci Rep, 9(5), 411 - 417, 2009.
  23. Viglietta V. et al.: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med, 199 (7), 971-979 , 2004.
  24. Zabłocka A., Janusz M.: Structure and function of the central nervous system. Postepy Hig Med Dosw (online), 61, 454-460, 2007.
prev next



July 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31